55052-24-9

Basic information

• Product Name: 7-OXIDE-7-AZAINDOLE
• Synonyms: 1H-Pyrrolo[2,3-β]pyridine 7-Oxide;1H-Pyrrolo[2,3-β]pyridine-N-oxide;1H-Pyrrolo[2,3-b]pyridine, 7-oxide;1H-Pyrrolo[2,3-b]pyridine-N-oxide;7-Azaindole N-oxide hemihydrate;7-Azaindole-7-oxide;7-Oxide-7-azaindole ,98%;7H-1$l^{5},7-pyrrolo[2,3-b][1$l^{5}]pyridin-1-one
• CAS NO: 55052-24-9
• Molecular Formula: C₇H₆N₂O
• Molecular Weight: 134.137
• Product Categories: Aromatics Compounds;Aromatics;Heterocycles;Heterocycle-Pyridine series
• Mol File: 55052-24-9.mol
• Article Data: 84

Chemical Properties

• Melting Point: 126-1280C
• Boiling Point: 352.677°C at 760 mmHg
• Flash Point: 167.093°C
• Appearance: /
• Density: 1.331g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.668
• Storage Temp.: Refrigerator
• Solubility: Chloroform, DMSO, Methanol
• PKA: 12.68±0.40(Predicted)
• CAS DataBase Reference: 7-OXIDE-7-AZAINDOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 7-OXIDE-7-AZAINDOLE(55052-24-9)
• EPA Substance Registry System: 7-OXIDE-7-AZAINDOLE(55052-24-9)

Safety Data

• Hazard Codes: Xn
• Statements: 22-41
• Safety Statements: 26
• RIDADR: UN 2811 6.1/PG 3
• Hazardous Substances Data: 55052-24-9(Hazardous Substances Data)

Usage

Chemical Properties

Beige Solid

Uses

1H-Pyrrolo[2,3-b]pyridine 7-Oxide (cas# 55052-24-9) is a compound useful in organic synthesis.

InChI:InChI=1/C7H6N2O/c10-9-5-1-2-6-3-4-8-7(6)9/h1-5,8H

Upstream product

• 74420-18-1 7-Hydroxy-1H-pyrrolo<2,3-b>pyridinium m-chlorobenzoate 
• 1374585-47-3 7-hydroxy-1H-pyrrolo[2,3-b]pyridinium 3-chloroperoxybenzoate 
• 272-49-1 1H-pyrrolo[3,2-b]pyridine 
• 271-63-6 7-Azaindole 

Downstream Products

• 143468-12-6 1-Benzoyl-6-bromo-1H-pyrrolo<2,3-b>pyridine 
• 74420-07-8 3-nitro-1H-pyrrolo<2,3-b>pyridine 7-oxide 
• 74420-06-7 4-nitro-1H-pyrrolo<2,3-b>pyridine 7-oxide 
• 55052-28-3 4-chloro-7-azaindole 
• 849068-50-4 ethyl 6-chloro-1H-pyrrolo[2,3-b]pyridine-1-carboxylate 
• 55052-25-0 1-acetyl-1H-pyrrolo[2,3-b]pyridin-6-yl acetate 
• 348640-07-3 4-bromo-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine 
• 916176-50-6 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine 
• 1246761-84-1 (1H-pyrrolo[2,3-b]pyridin-4-yl)boronic acid 
• 1352232-88-2 (3R)-3-methyl-4-(6-(1-(S-methylsulfonimidoyl)cyclopropyl)-2-(1-tosyl-1H-pyrrolo[2,3-b]pyridine-4-yl)pyrimidin-4-yl)morpholine 
• 1352227-13-4 (R)-3-methyl-4-(6-((R)-S-methylsulfonimidoylmethyl)-2-(1-tosyl-1H-pyrrolo[2,3-b]pyridin-4-yl)pyrimidin-4-yl)morpholine 
• 1352226-88-0 4-[4-[1-[[S(R)]-S-methylsulfonimidoyl]cyclopropyl]-6-[(3R)-3-methyl-4-morpholinyl]-2-pyrimidinyl]-1H-pyrrolo[2,3-b]pyridine 
• 1352226-87-9 4-{4-[(3R)-3-methylmorpholin-4-yl]-6-[1-((S)-S-methylsulfonimidoyl)cyclopropyl]pyrimidin-2-yl}-1H-pyrrolo[2,3-b]pyridine 
• 1352232-89-3 (3R)-3-methyl-4-(6-(1-((R)-S-methylsulfonimidoyl)cyclopropyl)-2-(1-tosyl-1H-pyrrolo[2,3-b]pyridin-4-yl)pyrimidin-4-yl)morpholine 

Relevant articles and documents

Synthesis and structure?activity?relationship of 3,4?Diaryl?1H?pyrrolo[2,3?b]pyridines as irreversible Inhibitors of mutant EGFR?L858R/T790M

The epidermal growth factor receptor (EGFR) is a well?validated drug target for the treatment of non?small cell lung cancer. Here we present an optimization approach and preliminary structure?activity relationship for 1H?pyrrolo[2,3?b]pyridines as covalent irreversible mutant EGFR inhibitors. We synthesized a focused library to investigate the effect of different aromatic substituents in the 4?position of this scaffold, interacting with the gatekeeper. We determined the activity of the synthesized compounds mutant EGFR enzyme assays and determined the selectivity over the wild type.

Inhibitors of the Hippo Pathway Kinases STK3/MST2 and STK4/MST1 Have Utility for the Treatment of Acute Myeloid Leukemia

Serine/threonine-protein kinases 3 and 4 (STK3 and STK4, respectively) are key components of the Hippo signaling pathway, which regulates cell proliferation and death and provides a potential therapeutic target for acute myeloid leukemia (AML). Herein, we

DERIVATIVES OF AN FGFR INHIBITOR

The present disclosure relates to derivatives (e.g., hydroxyl, keto, glucuronide, sulfonic acid, and deuterated) of a Fibroblast Growth Factor Receptors (FGFR) inhibitor, including methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of FGFR mediated disease such as cancer.

Ligand compound for copper catalyzed aryl halide coupling reaction, catalytic system and coupling reaction

The invention provides a ligand compound capable of being used for copper catalyzed aryl halide coupling reaction, the ligand compound is a three-class compound containing a 2-(substituted or non-substituted) aminopyridine nitrogen-oxygen group, and the invention also provides a catalytic system for the aryl halide coupling reaction. Thecatalytic system comprises a copper catalyst, a compound containing a 2-(substituted or non-substituted) aminopyridine nitrogen-oxygen group adopted as a ligand, alkali and a solvent, and meanwhile, the invention also provides a system for the aryl halide coupling reaction adopting the catalyst system. The compound containing the 2-(substituted or non-substituted) aminopyridine nitrogen oxygen group can be used as the ligand for the copper catalyzed aryl chloride coupling reaction, and the ligand is stable under a strong alkaline condition and can well maintain catalytic activity when being used for the copper-catalyzed aryl chloride coupling reaction. In addition, the copper catalyst adopting the compound as the ligand can particularly effectively promote coupling of copper catalyzed aryl chloride and various nucleophilic reagents which are difficult to generate under conventional conditions, C-N, C-O and C-S bonds are generated, and numerous useful small molecule compounds are synthesized. Therefore, the aryl halide coupling reaction has a very good large-scale application prospect by adopting the copper catalysis system of the ligand.